Table 2.
Laboratory tests for prediction of early mortality in acute PE.
| Biomarker | Cut-Off Value | Sensitivity, % (95% CI) | Specificity, % (95% CI) | NPV, % (95% CI) | PPV, % (95% CI) | OR or HR, % (95% CI) |
Study Design |
|---|---|---|---|---|---|---|---|
| NT pro BNP | ≥600 pg/mL | 81 | 56 | 99 | 1.9 | 8..7 (2.8–27) | Meta analysis [22] |
| BNP | 75–100 pg/mL | NR | NR | NR | NR | 6.5 (2.0–21) | Meta analysis [22] |
| Troponin T | ≥14 pg/mL for patients <75 years | 87 | 42 | 98 | 9 | 4.97 (1.71–14.43) |
Prospective cohort [16] |
| ≥45 pg/mL for patients ≥75 years | 83 (55–95) | 64 (58–70) | 99 | 11 | 9.05 (1.94–42.26) | Prospective cohort [33] | |
| H-FABP | 6 ng/mL | 71 (for clinical complication course at 30-day) |
74 (for clinical complication course) |
100 | 41 | 17.67 (46.02–51.89) | Meta-analysis [27] |
| 90 (for mortality at 30-day) |
72 (for mortality at 30-day) |
32.94 (8.80–123.21) | |||||
| Copeptin | ≥24 pmol/L | 62 (41–79) | 80 (77–82) | 99 | 7 | 6.33 (2.58–15.51) | Prospective cohort [25] |